Hunting Hill Global Capital’s Royalty Pharma RPRX Stock Holding History

Hunting Hill Global Capital’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$290K	Sell	6,036 -6,604	-52%	-$289K	0.22%	60
2025 Q4	$488K	Sell	12,640 -3,294	-21%	-$126K	0.34%	55
2025 Q3	$562K	Hold	15,934	–	–	0.16%	63
2025 Q2	$574K	Hold	15,934	–	–	0.16%	69
2025 Q1	$496K	Hold	15,934	–	–	0.3%	59
2024 Q4	$406K	Hold	15,934	–	–	0.15%	62
2024 Q3	$451K	Hold	15,934	–	–	0.43%	46
2024 Q2	$420K	Hold	15,934	–	–	0.19%	71
2024 Q1	$484K	Buy	+15,934	New	+$470K	0.24%	74

Other funds holding RPRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Hunting Hill Global Capital's RPRX Position: Q1 2026 in Review

Hunting Hill Global Capital reduced its Royalty Pharma (RPRX) stake by 52% in Q1 2026, selling an estimated $289K and leaving 6,036 shares worth $290K. The position accounts for 0.22% of the portfolio, ranked #60.

Hunting Hill Global Capital first reported a position in RPRX in Q1 2024 and has held it in 9 quarters since. The position peaked at $574K in Q2 2025. 587 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

Hunting Hill Global Capital held 6,036 shares of Royalty Pharma worth $290K as of Q1 2026.
Hunting Hill Global Capital sold 6,604 Royalty Pharma shares in Q1 2026, an estimated $289K.
Royalty Pharma made up 0.22% of Hunting Hill Global Capital's portfolio in Q1 2026, its #60 holding.
Hunting Hill Global Capital first reported a position in Royalty Pharma in Q1 2024 and has held it in 9 quarters since.
Hunting Hill Global Capital's Royalty Pharma position peaked at $574K in Q2 2025.
587 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on Hunting Hill Global Capital's 13F filing for Q1 2026, filed 15 May 2026.